Cybin Inc.

Biotechnology • Healthcare • Toronto, ON, United States • CYBN (ASE)

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.

100 King Street West, Toronto, ON M5X 1C9, Canada

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq - Yahoo Finance

Yahoo Finance • Dec 19

Cybin alters state to become Helus Pharma for Nasdaq trip - Fierce Pharma

Fierce Pharma • Dec 19

Cybin Initiates At-The-Market Equity Program of up to US$100 Million - Business Wire

Business Wire • Dec 30

Cybin 2026 Outlook: Clinical Milestones And Cash Position Set Stage For Momentum (CYBN) - Seeking Alpha

Seeking Alpha • Jan 2

Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq in Early January - TipRanks

TipRanks • Dec 22

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has CYBIN INC. had layoffs?

No layoff events have been recorded for CYBIN INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does CYBIN INC. have?

CYBIN INC. has approximately 50 employees.

What industry is CYBIN INC. in?

CYBIN INC. operates in the Biotechnology industry, within the Healthcare sector.

Is CYBIN INC. a publicly traded company?

Yes, CYBIN INC. is publicly traded under the ticker symbol CYBN on the ASE. The company has a market capitalization of approximately $0.42 billion.

Where is CYBIN INC. headquartered?

CYBIN INC. is headquartered in Toronto, ON, United States at 100 King Street West, Toronto, ON M5X 1C9, Canada.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.